Dendreon’s Seal Beach plant: advertising campaign aimed at boosting demand for company’s flagship product A top executive of Seattle-based biotech Dendreon Corp., which has a manufacturing plant in ...

(Reuters) - Dendreon Corp filed for Chapter 11 bankruptcy protection after sales of the world's first cancer vaccine fell short of expectations and left the company deep in debt. More than two-thirds ...

The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK). Seattle biotech company Dendreon is terminating a supply ...

Tough times continue for Dendreon Corp., the Seattle biotech company with a plant in Seal Beach, where the company just cut 70 jobs, according to a filing with the state Employment Development ...

It’s been more than a decade since Dendreon’s prostate cancer immunotherapy, Provenge, won FDA approval. Now, after a lackluster launch, a bankruptcy and multiple ownership changes, the biopharma is ...

Shares of biotech Dendreon (NASDAQ: DNDN) swooned more than two-thirds on Aug. 4 — hit by uncertainty surrounding its prostate cancer drug sales. Shares of biotech Dendreon (NASDAQ: DNDN) swooned more ...

Following reports last week of a bid, it has now been confirmed that the Canadian company Valeant Pharmaceuticals International Inc will buy Provenge-maker Dendreon. Valeant Pharmaceuticals ...

I’ve been working on projects and taking days off here and there, so the blog has suffered, and I’ve missed out on some good biotech tidbits in the past couple of weeks. In the region’s biotech ...

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, is pleased to announce the ...